Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis
Authors' conclusion
A combination of general health, HAQ-DI, EQ-5D and pain could aid as a screening tool for active disease in patients with RA and PsA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) (tREACH and TARA trials) and psoriatic arthritis (PsA) (DEPAR cohort)4,594 RA and 1154 PsA visits
- Participants
- 683 vs 525
- Comparison
- Sum score of deteriorated patient-reported outcome measure (PROMs) between two consecutive visits as a screening tool for active disease in RA and PsA
- RAn = 683
- PsAn = 525
- Outcome
- AUC of the sum score of deteriorated PROMs (general health VAS, HAQ-DI, pain VAS/NRS, EQ-5D, fatigue VAS/NRS, presenteeism) for detecting active disease
- Follow-up
- Between two consecutive visits
Methodological detailssecondary use of tREACH and TARA trials and DEPAR cohort data
- Secondary use of tREACH and TARA trials and DEPAR cohort data
Performance
As reported in the abstract
Discriminative ability of combined PROMs (general health, HAQ-DI, EQ-5D, pain) for active disease
| Test or model | AUC | Specificity (cut-point ≥1 deteriorated PROMs) | Sensitivity (cut-point ≥1 deteriorated PROMs) | Active disease visits overlooked |
|---|---|---|---|---|
| RA | 0.76 | 40% | 90% | 10% |
| PsA | 0.85 | 41% | 4% |
AUC
RA0.76
PsA0.85
Specificity (cut-point ≥1 deteriorated PROMs)
RA40%
PsA41%
Sensitivity (cut-point ≥1 deteriorated PROMs)
RA90%
PsA— not stated in the abstract
Active disease visits overlooked
RA10%
PsA4%
Further findings
Visits with active disease
Original publication
Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis. RMD Open. Published 18 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →